GVK Bio will use its drug discovery expertise to deliver a clinical candidate and Endo will develop and commercialize the product.
For GVK, the collaboration is also part of its newly initiated early discovery assets (EDA) business. “This collaboration confirms the value of our differentiated EDA concept, conceived to collaborate with pharmaceutical partners on discovery projects, from target to clinical candidates," Manni Kantipudi, chief executive officer of GVK Bio, said in a release on Monday.
Subscribe to Mint Newsletters
* Enter a valid email
* Thank you for subscribing to our newsletter.
Never miss a story! Stay connected and informed with Mint.
our App Now!!